WALVAX(SZ:300142)2022-12-06 08:32Group 1: Product Development and Clinical Research - The company is advancing several key products, including the 13-valent pneumococcal conjugate vaccine, HPV vaccine, trastuzumab biosimilar, and infliximab biosimilar, all of which are in Phase III clinical trials, aiming for unblinding in 2017 [2] - The 13-valent pneumococcal conjugate vaccine has completed participant enrollment and basic immunization [2] - The HPV vaccine has completed the full three-dose regimen and is currently conducting gynecological follow-ups and clinical sample testing [2] Group 2: Shareholder Developments - In September 2016, major shareholders signed a share transfer agreement with Yunnan Industrial Investment Group, transferring part of their shares [2] - As of November 11, 2016, Yunnan Industrial Investment Group holds 8% of the company's shares following the completion of the transfer registration [2] - The partnership with Yunnan Industrial Investment Group aims to provide comprehensive support, including funding, government subsidies, and strategic planning for the company's development in the biopharmaceutical and health sectors [2]